Press release
June 21, 2022

Owkin, the Francis Crick Institute and The Royal Marsden NHS Foundation Trust partner to use AI for kidney cancer evolution

Owkin is partnering with scientists from the Francis Crick Institute and The Royal Marsden NHS Foundation Trust in London to use artificial intelligence (AI) to research how the evolution of a kidney cancer tumor is linked to differences in its microscopic structure, with the ultimate goal of helping doctors to improve the way the disease is treated.

Kidney cancer rates are increasing, largely due to an aging population, increasing obesity and smoking. Research suggests that a possible reason for treatment failure is intratumor heterogeneity – distinct tumor cell populations within a tumor with differing molecular and phenotypical profiles. Treating the disease requires an understanding of the characteristics of an individual’s tumor, which can vary widely between patients. If doctors can predict a patient’s outcomes based on these characteristics, then they can tailor treatments to suit their individual needs – known as precision medicine.

To help to build the scientific basis for this, researchers from Owkin, the Crick Institute and The Royal Marsden NHS Foundation Trust are using AI to better understand how the evolution of renal cell carcinoma (RCC), the most common kidney cancer, relates to tumor histology. By using AI to analyze over 1000 tissue samples from 100 different tumors, researchers hope to find a way to predict unique evolutionary features in every patient. These features in turn can predict patient outcomes.

Image 1. Tumor evolution can be grouped into three categories (or “modes” of evolution) that are associated with clinical outcomes. They are characterized by differing levels of chromosomal complexity (or weighted genomic instability, a measure of how unstable the genome is) and intratumoral heterogeneity.

Some kidney cancers grow very slowly, while others grow rapidly and spread around the body, making it challenging to predict outcomes for individual patients. However, evolutionary features – meaning how the tumor has evolved through a series of genetic changes over time – associate closely with specific outcomes. By deploying machine learning to better understand how these outcomes relate to histological characteristics of the tumor, the project aims to improve our fundamental understanding of disease mechanics and help the transition to precision medicine.

Dr Samra Turajlic, Group Leader at the Francis Crick Institute and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said:

We know that the outcomes of any individual patient with kidney cancer are determined by the distinct way their tumor evolves. We want to be able to predict the next step in a tumor’s evolutionary trajectory and better tailor treatments that can effectively tackle a patient’s cancer. New technologies and tools are critical in helping us achieve this at a scale and speed that is required in clinical practice, and at a cost that will make these measurements implementable in most healthcare systems.

Thomas Clozel MD, Co-founder and CEO of Owkin, said:

Owkin’s mission is to find the right treatment for every patient. By using AI to improve our fundamental understanding of kidney cancer tumors, we aim to enable doctors to move towards a precision medicine approach to treatment. We are excited to be working with the Crick Institute and the Royal Marsden Hospital to make a lasting difference to the lives of patients.

By using rapid and low-cost AI on digital pathology slides rather than large-scale genomic sequencing, which can be cost-prohibitive, the project hopes to help the day-to-day management of patients in a cost-effective, implementable way.

For clinical settings, the project opens new possibilities for the interpretation of routine kidney cancer biopsies. For research settings, the project aims to discover valuable insights into the interindividual differences in tumour evolution, progression and treatment resistance, building our scientific understanding of how to best treat kidney cancer.

Image 2. A high magnification micrograph of a clear cell renal cell carcinoma (RCC).

Cases of renal cell carcinoma (RCC) have more than doubled in the UK since the late 1970s to around 10,000 new diagnoses every year. 50% of patients present with advanced disease and have a five-year survival rate of just 5%. Since the early 1970s, the mortality rate for kidney cancer in the UK has increased by almost three-quarters (73%).

The project supports the work of TRACERx (TRAcking Cancer Evolution through therapy (Rx)), a major translational research study aimed at transforming our understanding of cancer evolution and moving towards an era of precision medicine. TRACErX Renal has received funding from Cancer Research UK, the NIHR Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research, London, and The Royal Marsden Cancer Charity.

About the Crick Institute

The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the fundamental biology underlying health and disease. Its work is helping to understand why disease develops and to translate discoveries into new ways to prevent, diagnose and treat illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases.

An independent organisation, its founding partners are the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King’s College London.

The Crick was formed in 2015, and in 2016 it moved into a brand new state-of-the-art building in central London which brings together 1500 scientists and support staff working collaboratively across disciplines, making it the biggest biomedical research facility under a single roof in Europe.

About The Royal Marsden NHS Foundation Trust

The Royal Marsden opened its doors in 1851 as the world’s first hospital dedicated to cancer diagnosis, treatment, research and education.

Today, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer center in Europe seeing and treating over 59,000 NHS and private patients every year.  It is a center of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies.

The Royal Marsden, with the ICR, is the only National Institute for Health Care Research Biomedical Research Centre for Cancer. This supports pioneering research work carried out over a number of different cancer themes.

The Royal Marsden Cancer Charity raises money solely to support The Royal Marsden, a world-leading cancer center.  It ensures Royal Marsden nurses, doctors and research teams can provide the very best care and develop life-saving treatments, which are used across the UK and around the world.

From funding state-of-the-art equipment and ground-breaking research, to creating the very best patient environments, The Royal Marsden Cancer Charity will never stop looking for ways to improve the lives of people affected by cancer.

About Owkin

Owkin is the first full-stack TechBio company on a mission to understand complex biology and derive new multimodal biomarkers through AI.

We identify precision therapeutics, de-risk and accelerate clinical trials and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular, immunity and inflammation.

Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across seven cancer indications.

Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like Fidelity, GV and Bpifrance, among others.